Abaloparatide lub luag haujlwm hauv pob txha noj qab haus huv yog dab tsi?
Dec 29, 2025
Tso lus
Taw qhia
Tus neeg twg uas tau siv sijhawm rau kev tshawb fawb osteoporosis thaum kawg yuav ntsibAbaloparatide-cov peptide hluavtaws nrog lub luag haujlwm tshwj xeeb: txhawb kev tsim cov pob txha yam tsis muaj kev txaus siab rau lub cev uas ua rau cov pob txha sib npaug. Cov tshuaj tau sau cov pov thawj txaus los ua pov thawj nws qhov chaw hauv cov pob txha niaj hnub no - cov tswv yim kev noj qab haus huv. Dab tsi hauv qab no tsis yog daim ntawv tshaj tawm, tab sis kev tshawb nrhiav cov lus nug tseem ceeb hauv ntiaj teb kev tshawb fawb thiab kev kho mob cov zej zog yuav nug txog nws.
Dab tsi yog Abaloparatide?
Ntawm nws cov tub ntxhais, Abaloparatide yog ib qho piv txwv ntawm tib neeg cov tshuaj hormones parathyroid ntsig txog cov protein, tshwj xeeb yog tsim los txhawb txoj kev pom kev anabolic (PTH1 receptor RG conformation). This design is intentional: the goal is to tip the scale toward osteoblast stimulation without excessively activating osteoclasts. Lub molecule nws tus kheej yog ib tug 34-amino-acid peptide, tsim nyob rau hauv nruj purity tswj, feem ntau muab raws li ib tug lyophilized hmoov rau downstream formulation.
Thaum nws cov qauv qauv molecular zoo ib yam li PTH thiab teriparatide, qhov kev hloov pauv hloov maj mam hauv nws cov kab ke cuam tshuam rau receptor binding kinetics. Cov kev hloov pauv no- me me rau qhov muag liab qab- txhais ua qhov sib txawv ntawm qhov muaj txiaj ntsig zoo.
Dab tsi Physiological Shifts Abaloparatide Qhia?
Thaum muab tshuaj, Abaloparatide khi rau PTH1 receptor, tab sis tsis zoo ib yam thoob plaws txhua lub xeev receptor. Nws qhov kev nyiam rau RG lub xeev ua rau muaj kev cuam tshuam ntau dua ntawm cov teeb liab intracellular. Hauv kev xyaum, qhov no txhais tau tias:
Kev nce ceev hauv cov pob txha- cov cim tsim;
Tsawg nce ntawm resorption markers;
Thiab muaj txiaj ntsig zoo rau cov pob txha loj.
Los ntawm kev pom kev lom neeg, cov peptide thawb cov pob txha metabolism mus rau kev tsim kev tswj hwm -ib qho tsis tshua muaj hauv kev kho mob pob txha.
Nws Puas Muaj Kev Pabcuam Zoo rau Osteoporosis?
Ntawm cov poj niam postmenopausal uas muaj kev pheej hmoo ntawm pob txha, Abaloparatide tsis tu ncua ua kom muaj zog hauv pob txha pob txha pob txha ntom ntom (BMD). Qhov kev sim tshuaj ACTIVE tseem yog cov ntaub ntawv keeb kwm keeb kwm: vertebral fracture pheej hmoo poob qis dua piv nrog cov placebo, thiab kev txhim kho tau tshwm sim ntxov hauv kev kho mob. Radial thiab femoral qhov chaw pom tau tias muaj kev txhim kho zoo ib yam, txawm hais tias qhov loj me txawv ntawm tus neeg mob profile thiab cov pob txha loj.
Puas yog Abaloparatide muaj kev nyab xeeb lossis zoo dua li Teriparatide?
Lub taub hau-rau- kev tshuaj ntsuam lub taub hau qhia tau hais tias Abaloparatide ua rau muaj qhov loj me me hauv BMD ntawm ntau qhov chaw pob txha thiab tej zaum yuav ua rau muaj tsawg dua ntu ntawm hypercalcemia. Mechanistically, lub luv luv receptor- ua kom lub qhov rais cuam tshuam nrog Abaloparatide yog qhov sib txawv tseem ceeb thiab ib qho laj thawj kws kho mob feem ntau sib tham txog nws li "tsawg calcium-mobilizing" anabolic.
| Parameter | Abaloparatide | Teriparatide |
|---|---|---|
| Receptor Affinity | Xaiv rau RG (Active) xeev | Kev ua kom dav dua PTH1R |
| Hypercalcemia Risk | Tsawg qhov xwm txheej | Kev soj ntsuam ntau dua |
| Teeb liab Transduction | Transient (lub qhov rais luv) | Txhawb nqa ntxiv |
Ntev npaum li cas ua ntej kev txhim kho tuaj yeem kuaj tau?
Cov pob txha- cov cim tsim pib hloov hauv lub lis piam. Kev txhim kho BMD ntau, txawm li cas los xij, feem ntau xav tau ob peb lub hlis los sau npe. Cov txheej txheem txheej txheem yog ib zaug - txhaj tshuaj subcutaneous ib hnub ntawm 80 ug. Qhov kev kho mob ntev ntev caps ntawm18 hli, tom qab uas cov neeg mob hloov mus rau tus neeg sawv cev antiresorptive kom khaws tau cov txiaj ntsig.
Puas yog Ntev -Tsev Siv Sijhawm Uas Muaj Teeb Meem Zoo li Osteosarcoma?
Cov ntaub ntawv tib neeg tam sim no- suav nrog ntau xyoo - xyoo ua raws - nce ntxiv - tsis qhia meej meej qhia txog kev pheej hmoo siab osteosarcoma hauv chaw kho mob. Txhais cov nas pob txha biology rau tib neeg tsis yog yooj yim. Txawm li cas los xij, cov lus qhia tseem muaj kev saib xyuas, tuav lub hau 18 lub hlis raws li kev ceev faj.
Dab tsi yuav tsum muaj kev cuam tshuam?
Sab -cov txiaj ntsig profile feem ntau tuaj yeem kwv yees tau: kiv taub hau ib ntus, kev txhaj tshuaj me me- qhov tshwm sim ntawm qhov chaw, thiab kev hloov pauv me ntsis hauv cov ntshav calcium. Cov xwm txheej ntawm cov hlab plawv tsis tshua muaj tab sis tau saib xyuas zoo hauv cov neeg uas muaj qhov tsis txaus ntseeg.
Cov txiv neej lossis cov neeg mob uas txo lub raum ua haujlwm puas siv tau?
Cov ntaub ntawv loj hlob tam sim no suav nrog cov txiv neej uas muaj pob txha, uas qhia cov lus teb zoo sib xws. Rau lub raum tsis zoo, qhov ua tsis taus me me mus rau nruab nrab feem ntau tso cai rau kev noj tshuaj, thaum qhov kev puas tsuaj loj yuav tsum tau txiav txim siab hauv tsev kho mob vim tias kev tshem tawm peptide yog ib feem ntawm lub raum- nyob ntawm.
Puas yog Abaloparatide tsim nyog rau kev sib xyaw ua ke?
Kev kho mob raws sij hawm-anabolic thawj zaug, antiresorptive thib ob- tau txais txiaj ntsig zoo dua los ntawm cov pov thawj dua li kev sib xyaw ua ke. Abaloparatide tau lees paub nyob rau hauv "muaj zog anabolic, zoo teb sai" qeb rau kev tiv thaiv pob txha.
Vim li cas thiaj xav txog Xi'an Tihealth Biotechnology's Abaloparatide API?
Los ntawm kev tsim khoom,Xi'an Tihealth Biotechnology Co., Ltd. qhia txog kev tswj peptide synthesis thiab multi-theem analytical verification (HPLC, Mass Spectrometry, residual solvent profileing). Peb lub chaw ua haujlwm nyob rau hauv ISO9001: 2015 cov txheej txheem ua haujlwm zoo, tso cai rau API ua tiav- cov neeg tsim tshuaj txhaj tshuaj nrhiav kev ua kom huv huv thiab ua kom muaj kev ruaj ntseg.
Hauv peptide-API ntu, kev tsim tawm tseem ceeb dua li cov txiaj ntsig theoretical. Peb tso peb cov kev txawj ntse ntawm qhov axis.
Kev ntseeg tau tus khub rau pob txha noj qab haus huv cov khoom xyaw
Pab 1,500+ cov neeg siv khoom thoob ntiaj teb nrog cov tshuaj ntsuab zoo tshaj plaws thiab API Peptides.
ThovAbaloparatideSpecification / COA
Cov ntaub ntawv
Miller PD et al. "Qhov cuam tshuam ntawm Abaloparatide vs Placebo ntawm Tshiab Vertebral Fractures hauv Cov Poj Niam Postmenopausal."JAMA. 2016.
https://jamanetwork.com/journals/jama/fullarticle/2524181
Hattersley G et al. "Mechanism ntawm Kev Ua ntawm Abaloparatide."Calcified Tissue International.
https://link.springer.com/article/10.1007/s00223-016-0175-5
FDA Pom Zoo Tshuaj Pob rau Abaloparatide.
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208743Orig1s000TOC.cfm
ACTIVE Trial Clinical Summary.
https://clinicaltrials.gov/ct2/show/NCT01343004
Xa kev nug